Zura Bio (ZURA) Reports Q3, Provides Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Wall St set for higher open after Micron revives AI optimism, upbeat economic data
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 13, 2023 6:30 AM ESTInitiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026
HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq:... More
